CA
NZ
UK
AU
IND
US
La-Z-Boy Incorporated filed an 8-K on August 26, 2026, reporting the final voting results from its 2026 Annual Meeting of Shareholders held on August 25, 2026, covering director elections, auditor ratification, and executive compensation approval.
NVIDIA Corporation filed its Form 10-Q with the U.S. Securities and Exchange Commission for the quarterly period ended July 26, 2026, reporting condensed consolidated financial statements covering both the three and six months ended on that date.
Unum Group filed a Form 8-K with the SEC on August 26, 2026, disclosing that its Board of Directors has authorized the repurchase of up to $1 billion of its outstanding common stock under a new program set to begin September 1, 2026.
NVIDIA Corporation filed a current report on Form 8-K with the U.S. Securities and Exchange Commission on August 26, 2026, announcing the attachment of its press release and CFO commentary covering financial results for the second quarter of fiscal year 2027.
Bath & Body Works, Inc. filed its quarterly report on Form 10-Q with the SEC for the thirteen-week period ended August 1, 2026, disclosing second-quarter and year-to-date financial results.
Phibro Animal Health Corporation filed its Annual Report on Form 10-K with the U.S. Securities and Exchange Commission on August 26, 2026, covering the fiscal year ended June 30, 2026.
Phibro Animal Health Corporation filed a Form 8-K with the U.S. Securities and Exchange Commission on August 26, 2026, disclosing operating results for its fourth quarter and fiscal year ended June 30, 2026, along with financial guidance for the fiscal year ending June 30, …
Blackstone Holdings II L.P. and affiliated reporting persons filed a Form 4 on August 26, 2026, disclosing a series of transactions in Class A and Class B Common Stock of Jersey Mike's Subs Inc. (NASDAQ:JMKE) dated August 24-25, 2026.
Abhimanyu Verma, Chief Technology Officer of SOPHiA GENETICS SA (NASDAQ:SOPH), filed a Form 4 on August 26, 2026, disclosing two open-market sales of ordinary shares totaling 10,000 shares executed on August 19 and August 24, 2026, pursuant to a Rule 10b5-1 trading plan.
Philippe Menu, Chief Medical Officer of SOPHiA GENETICS SA (NASDAQ:SOPH), filed a Form 4 on August 26, 2026, disclosing the sale of 5,000 ordinary shares on August 25, 2026, under a Rule 10b5-1 trading plan.
Please wait processing your request...